x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Chung, Wendy KRemove Chung, Wendy K filter
- El-Gharbawy, AreegRemove El-Gharbawy, Areeg filter
Publication Date
Please choose a date range between 2010 and 2019.
Author
- Arn, Pamela2
- Austin, Stephanie L2
- Bali, Deeksha S2
- Kishnani, Priya S2
- Watson, Michael S2
- Weinstein, David A2
- Bachrach, Bert1
- Boney, Anne1
- Brown, Laurie M1
- Case, Laura E1
- Desai, Dev M1
- Goldstein, Jennifer1
- Haller, Ronald1
- Hobson-Webb, Lisa D1
- Kahler, Stephen1
- Pendyal, Surekha1
- Ross, Katalin M1
- Smit, G Peter A1
- Smith, Alastair D1
- Tsilianidis, Laurie1
- Wechsler, Stephanie Burns1
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
2 Results
- ACMG Practice ResourceOpen Archive
Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
Genetics in MedicineVol. 21Issue 4p772–789Published in issue: April, 2019- Priya S. Kishnani
- Jennifer Goldstein
- Stephanie L. Austin
- Pamela Arn
- Bert Bachrach
- Deeksha S. Bali
- and others
Cited in Scopus: 61Glycogen storage disease (GSD) types VI and IX are rare diseases of variable clinical severity affecting primarily the liver. GSD VI is caused by deficient activity of hepatic glycogen phosphorylase, an enzyme encoded by the PYGL gene. GSD IX is caused by deficient activity of phosphorylase kinase (PhK), the enzyme subunits of which are encoded by various genes: ɑ (PHKA1, PHKA2), β (PHKB), ɣ (PHKG1, PHKG2), and δ (CALM1, CALM2, CALM3). Glycogen storage disease types VI and IX have a wide spectrum of clinical manifestations and often cannot be distinguished from each other, or from other liver GSDs, on clinical presentation alone. - ACMG-Practice-GuidelinesOpen Archive
Glycogen Storage Disease Type III diagnosis and management guidelines
Genetics in MedicineVol. 12Issue 7p446–463Published in issue: July, 2010- Priya S. Kishnani
- Stephanie L. Austin
- Pamela Arn
- Deeksha S. Bali
- Anne Boney
- Laura E. Case
- and others
Cited in Scopus: 186Glycogen storage disease type III is a rare disease of variable clinical severity affecting primarily the liver, heart, and skeletal muscle. It is caused by deficient activity of glycogen debranching enzyme, which is a key enzyme in glycogen degradation. Glycogen storage disease type III manifests a wide clinical spectrum. Individuals with glycogen storage disease type III present with hepatomegaly, hypoglycemia, hyperlipidemia, and growth retardation. Those with type IIIa have symptoms related to liver disease and progressive muscle (cardiac and skeletal) involvement that varies in age of onset, rate of disease progression, and severity.